First conditional marketing authorization approval in the European Union for hemophilia "A" gene therapy

Affiliations

¹ Department of Gene Therapy & Regenerative Medicine, Vrije Universiteit Brussel, Brussels, Belgium; Center for Molecular & Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium. Electronic address: thierry.vandendriessche@vub.be.
² Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, MI, USA.
³ World Federation of Hemophilia, Montreal, QC, Canada.
⁴ Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA. Electronic address: rkaczmar@iu.edu.

Editorial

Thierry VandenDriessche et al. Mol Ther. 2022.

. 2022 Nov 2;30(11):3335-3336.

doi: 10.1016/j.ymthe.2022.09.020. Epub 2022 Oct 19.

¹ Department of Gene Therapy & Regenerative Medicine, Vrije Universiteit Brussel, Brussels, Belgium; Center for Molecular & Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium. Electronic address: thierry.vandendriessche@vub.be.
² Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, MI, USA.
³ World Federation of Hemophilia, Montreal, QC, Canada.
⁴ Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA. Electronic address: rkaczmar@iu.edu.

No abstract available

References

1. Evens H., Chuah M.K., VandenDriessche T. Haemophilia gene therapy: from trailblazer to gamechanger. Haemophilia. Haemophilia. 2018;24:50–59. doi: 10.1111/hae.13494. - DOI - PubMed
1. Ozelo M.C., Mahlangu J., Pasi K.J., Giermasz A., Leavitt A.D., Laffan M., Symington E., Quon D.V., Wang J.D., Peerlinck K., et al. Valoctocogene roxaparvovec gene therapy for hemophilia A. N. Engl. J. Med. 2022;386:1013–1025. doi: 10.1056/NEJMoa2113708. - DOI - PubMed
1. Pasi K.J., Laffan M., Rangarajan S., Robinson T.M., Mitchell N., Lester W., Symington E., Madan B., Yang X., Kim B., et al. Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A. Haemophilia. 2021;27:947–956. doi: 10.1111/hae.14391. - DOI - PMC - PubMed
1. George L.A., Monahan P.E., Eyster M.E., Sullivan S.K., Ragni M.V., Croteau S.E., Rasko J.E.J., Recht M., Samelson-Jones B.J., MacDougall A., et al. Multiyear factor VIII expression after AAV gene transfer for hemophilia A. N. Engl. J. Med. 2021;385:1961–1973. doi: 10.1056/NEJMoa2104205. - DOI - PMC - PubMed
1. Butterfield J.S., Yamada K., Bertolini T.B., Syed F., Kumar S.R., Li X., Arisa S., Piñeros A.R., Tapia A., Rogers C.A., et al. IL-15 blockade and rapamycin rescue multifactorial loss of factor VIII from AAV-transduced hepatocytes in hemophilia A mice. Mol. Ther. 2022 doi: 10.1016/j.ymthe.2022.07.005. S1525-0016(22)00426-9. - DOI - PMC - PubMed